CHD/Prevention News

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone improved outcomes compared with placebo regardless of baseline diabetes status, according to new data from the FINEARTS-HF trial.

Adults with type 2 diabetes at high risk for cardiovascular events were more likely to sustain an HbA1c of 6.5% or less at 2 years with tirzepatide if they lost more weight and had improved beta-cell function, according to new data.

Among people who had ever smoked, those who quit had reduced risk for incident atrial fibrillation compared with those who had not, according to new data from the UK Biobank.

High consumption of ultraprocessed food, especially processed meats and sugar-sweetened beverages, was associated with elevated risk for heart disease and stroke, researchers reported.

Bariatric surgery for weight loss was associated with improvements in blood pressure and antihypertensive use among patients with obesity compared with medical therapy and/or lifestyle management, a speaker reported.

Exposure to higher amounts of some types of per- and polyfluoroalkyl substances during pregnancy may lead to long-term increases in body weight, waist circumference and fat mass, according to new findings.

The Cardiometabolic Health Congress announced that Peter Libby, MD, one of the foremost authorities in atherosclerosis, will deliver the keynote address at its upcoming 19th annual conference.

Semaglutide cut the risk for worsening heart failure and CV death for adults with HF with preserved ejection fraction, according to data presented at the European Society of Cardiology Congress and simultaneously published in The Lancet.

A single combined measure of three modifiable biomarkers in healthy women at midlife was predictive of 30-year risk for future cardiovascular events, according to new research presented at the European Society of Cardiology Congress.

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone reduced risk for CV death and worsening HF by 16% compared with placebo, researchers reported at the European Society of Cardiology Congress.